Articles tagged "Hepatitis C"

2022 American Transplant Congress
The SHELTER Trial of Transplanting Donor Hepatitis C Virus RNA+ Lungs Into Uninfected Recipients
V. Potluri¹, P. Reese¹, S. Prenner¹, H. Mentch¹, D. Goldberg², T. Claridge¹, J. Smith¹, C. Gentile¹, V. Van Deerlin¹, R. Reddy¹, T. Fallah¹, C. Bermudez¹, M. Crespo¹, J. Diamond¹
¹University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: The advent of direct acting antiviral therapy has motivated centers to transplant lungs from donors with hepatitis C virus infection (HCV-RNA+) into uninfected recipients.…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
CMV Specific T Cell Immune Response in Hepatitis C Negative Kidney Transplant Recipients Receiving Transplant from Hepatitis C Viremic Donors and Hepatitis C Negative Donors
M. Z. Molnar¹, M. Tsujita², M. Talwar², V. Balaraman², A. Bhalla², J. D. Eason², S. S. Nouer², K. Sumida², A. Remport³, I. E. Hall¹, R. Griffin², G. George Rofaiel⁴, A. Azhar⁵
¹Department of Internal Medicine, Division of Nephrology & Hypertension, University of Utah, Salt Lake City, UT, ²University of Tennessee Health Science Center, Memphis, TN, ³Semmelweis University, Budapest, Hungary, ⁴Department of Surgery, Division of Transplantation and Advanced Hepatobiliary Surgery, University of Utah, Salt Lake City, UT, ⁵Division of Nephrology, Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA
*Purpose: Kidney transplants (KT) from hepatitis C (HCV) viremic donors to HCV negative recipients has shown promising short-term and long-term outcomes. However, high incidence of…
2022 American Transplant Congress
National Consortium Registry Insights on Management and Outcome of Hepatitis C Viremic Heart Transplants
R. Gottlieb¹, M. Salem¹, A. Ravichandran², J. Kennedy³, J. Strope⁴, S. Lin⁵, J. Chow⁶, P. Eckman⁷, S. Desai⁸, O. Larkins¹, J. Vanzyl¹, S. Hall¹
¹Baylor Scott & White Healthcare, Dallas, TX, ²Ascension Medical Group, Indianapolis, IN, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Washington Medical Center, Seattle, WA, ⁶Tufts Medical Center, Boston, MA, ⁷Minneapolis Heart Institute, Minneapolis, MN, ⁸Ochsner Medical Center, New Orleans, LA
*Purpose: Multicenter US registry of clinical management of HCV NAT+ hearts.*Methods: An ongoing 8-center retrospective IRB-approved registry collected baseline characteristics, labs, management, and outcomes after…
2022 American Transplant Congress
Renal Transplants In Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Using Two Weeks Of DAA Prophylaxis (Rehanna – 2)
N. M. Desai¹, S. Leung¹, J. Motter¹, F. Naqvi², N. Bair¹, B. Barnaba², D. Warren¹, D. Segev¹, C. Durand²
¹Surgery, Johns Hopkins University, Baltimore, MD, ²Medicine, Johns Hopkins University, Baltimore, MD
*Purpose: To mitigate the organ shortage and underutilization of hepatitis C-infected deceased donor (HCV D+) organs, we evaluated the use of HCV D+ kidneys in…
2022 American Transplant Congress
Hypothermic Pulsatile Flush of Hepatitis C Virus (HCV) RNA Positive Kidney Reduces Viral Load
A. Jain¹, W. Greene²
¹Transplant Surgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, ²Dept. of Pathology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA
*Purpose: Does Hypothermic pulsatile flush of hepatitis C virus (HCV) RNA positive kidney reduce the viral load?*Methods: Unutilized, HCV RNA-positive deceased donor kidneys were obtained…
2022 American Transplant Congress
Kidney Transplant Alone Recipients with Advanced Liver Disease Have Similar Outcomes to Those without Advanced Liver Disease
R. R. Nathani, S. M. Rutledge, C. Villarroel, R. Shapiro, G. Y. Im
Icahn School of Medicine at Mount Sinai, New York, NY
*Purpose: The prevalence of concomitant liver disease (CLD) in patients with ESRD is reported to be 7-40%. Safety of kidney transplant alone (KTA) in those…
2022 American Transplant Congress
Compliance with OPTN Infectious Disease Testing
L. Irwin
Massachusetts General Hospital, Boston, MA
*Purpose: Effective 3/1/21 OPTN policy requires all transplant recipients to have pre-transplant and post-transplant infectious disease testing performed at specific intervals: upon admission and prior…
2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
B. Aqel¹, H. Khamash², A. Moss³, D. E. Steidley⁴, R. C. Dickson¹
¹Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ²Nephrology and Hypertension, Mayo Clinic, Phoenix, AZ, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Cardiology, Mayo Clinic, Phoenix, AZ
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
M. Person, N. Patel, W. Simerlein, H. Meadows, D. DuBay, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…